amesh adalja, thank you very much, sir.imes you are asking about the end of the show and not the pandemic. [laughter] lisa: i love your question to him is, are you going to ring the bell and say it is over? jonathan: i wonder what people are waiting for? does someone go on tv? president did that last year and it didn't work out, did it? lisa: i think a lot of people are treating it like it is over. we are hearing about the resurgence of cases in europe, and you raised the question to start with -- does it matter? should we even be tracking the cases the way we are? would it be that sensational to see the rise and fall of various illness? if we are not seeing the hospitalizations and deaths it doesn't have the same application for socialization and economy. jonathan: the older measurement of whether this is older or not is the health care system, hospitals. are they overwhelmed? in the doctors opinion, no. lisa: hopefully they stay that way and ba.2 doesn't start to cause problems given most americans are vaccinated. i think

the older you are doctor amish adalja, senior scholar at johns hopkins center for health security telling newsnation the plan to boost older americans again makes sen e. >> but he and other doctors have stressed that for younger people, the vaccines and first booster still offer good protection from severe disease, hospitalization and death. i think it's really important that this be a targeted boost, not something that the general public needs, but one that's actually based upon where we see evidence of erosion of protection. >> so people above 50 would be one area where that could be the case. just last week, the white house told the public without more funding from congress, it won't have the money to provide all americans with a 4th shot. the booster plan for people over 50 reportedly aimed at protecting older americans ahead of any new potential wave. the cdc's director recently saying scientists were studying the evidence about a 4th dose. and so as we are following those daytime, we're also working within the fda and with our pharmaceutical partners, of course, to understand the be

adalja was saying it is not leading to deaths or hospitalizations so far.onathan: the doctor is more fed up than we are. associate professor of emergency medicine at johns hopkins joins us now. how much better are things now versus two years ago as we deal with a new subvariant? >> there are so many more tools. in the past, we had a lot of unknowns, a lot of hospitalizations, a lot of loved ones dying. right now, we have test and treat programs. we have vaccinated individuals and vaccination levels are high and we have great policy and procedures in place to protect children less than five and patients in immuno comfort my states. this is a test for normality. can we survive the covid subvariant and can that subvariant not cause a strain on the health system? ? can we provide care for people with medical issues other than covid in an adequate matter? if we can, we can put on the brakes. lisa: let's fast-forward and see when we can say it worked according to plan and we never have to talk about it again. dr. hansoti: if you watch the u.k., they are starting

. >> doctor amish adalja, senior scholar at johns hopkins center for health security telling newsnation the plan to boost older americans again makes sense. but he and other doctors have stressed that for younger people, the vaccines and first booster still offer good protection from severe disease, hospitalization and death. i think it's really important that this be a targeted boost, not something that the general public needs, but one that's actually based upon where we see evidence of erosion of protection. >> so people above 50 would be one area where that could be the case. just last week, the white house told the public without more funding from congress, it won't have the money to provide all americans with a 4th shot. the booster plan for people over 50 reportedly aimed at protecting older americans ahead of any new potential wave. the cdc's director recently saying scientists were studying the evidence about a 4th dose. and so as we are following those daytime, we're also working within the fda and with our pharmaceutical partners, of course, to understand the benefit of that